Authors

Duan Jiang#, Aojie Liu, Wei Ling

Departments

Department of Pediatrics, Renmin Hospital Wuhan University, Wuhan, PR China

Abstract

Objective: To analyse the effects of levosimendan on serum endothelial cell specific molecule 1 (ESM-1), procalcitonin (PCT), and high-mobility group protein B1 (HMGB1) in patients with sepsis. 

Methods: Sixty patients with sepsis treated in the intensive care unit of our hospital from November 2015 to October 2016 were randomly divided into a control group and an observation group, with 30 cases in each group. The control group had traditional treatment while the observation group was treated with levosimendan on the basis of traditional treatment. Changes in the Marshall score, APACHEII score, and ESM-1, PCT, and HMGB1 levels were compared between the two groups before and after treatment.

Results: After treatment, the Marshall scores and APACHEII scores of the two groups were significantly lower than before treatment. These scores of the observation group were remarkably lower than those of the control group, with a statistically significant difference (P<0.05). After 3 days and 7 days of treatment, the serum ESM-1 levels of the two groups were lower than before treatment (P<0.05). Moreover, compared with the control group, there was a more obvious decrease of ESM-1 in the observation group, with a statistically significant difference (P < 0.05). After 3 days and 7 days of treatment, the level of PCT in the observation group was markedly lower than before treatment, and the level was significantly lower than that in the control group, with a statistically significant difference (P<0.01). After 3 days and 7 days of treatment, the concentration of HMGB1 in the observation group was significantly lower than before treatment (P<0.05), and the HMGB1 concentration in the observation group was obviously lower than that in the control group at each time point, with a statistically significant difference (P<0.05).

Conclusion: Levosimendan is effective in the treatment of sepsis and can obviously improve the function of vascular endothelial cells, reduce the inflammatory reaction, delay the progress of the disease, and improve the prognosis of patients.

Keywords

Levosimendan, sepsis, serum endothelial cell specific molecule 1 (ESM-1), procalcitonin (PCT), high-mobility group protein B1 (HMGB1).

DOI:

10.19193/0393-6384_2020_3_214